Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer
Journal of Medicinal Chemistry · 14.11.2024 · 67 (21) · 19395-19416
DOI: 10.1021/acs.jmedchem.4c01752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.11.2024. Verfasst von Jinbiao Liao und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 31005…. Hauptthemen laut MEDLINE: Coumarins, Prostatic Neoplasms, Androgen Receptor Antagonists, Receptors, Androgen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Androgen receptor (AR) is a crucial driver of prostate cancer (PCa), but acquired resistance to AR antagonists significantly undermines their clinical efficacy. We previously discovered coumarin derivative 1, which is capable of disrupting AR ligand-binding domain dimers, offering the potential for overcoming resistance. However, its poor oral bioavailability limited further development. In this study, comprehensive structure optimizations led to compound 4a (IC50 = 0.051 μM), which exhibited comparable AR antagonistic activity to enzalutamide (IC50 = 0.060 μM) and demonstrated excellent selectivity over other nuclear receptors in vitro. Especially, 4a showed superior efficacy against ARF876L/T877A and ARW741C mutants compared to darolutamide and enzalutamide. Moreover, 4a exhibited favorable pharmacokinetic profiles (F = 66.24%) in vivo and significant tumor growth inhibition in an LNCaP xenograft mouse model upon oral administration. These results highlight the potential of 4a as a promising oral AR antagonist for overcoming drug resistance in PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
- Jinhua Institute of Zhejiang University, Jinhua 321000 Zhejiang, China.
ORCID-Profile: Jinbiao Liao, Tingjun Hou, Dan Li, Rong Sheng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Liao, J., Liao, J., Zhang, M., Yu, Y., Cai, L., Le, K., Fu, W., Qin, Y., Hou, T., Li, D., & Sheng, R. (2024). Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer. Journal of Medicinal Chemistry, 67(21), 19395-19416. https://doi.org/10.1021/acs.jmedchem.4c01752
Vancouver
Liao J, Liao J, Zhang M, Yu Y, Cai L, Le K, et al. Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer. Journal of Medicinal Chemistry. 2024;67(21):19395-19416. doi:10.1021/acs.jmedchem.4c01752
BibTeX
@article{Liao2024,
author = {Liao, Jinbiao and Liao, Jianing and Zhang, Minkui and Yu, Yanzhen and Cai, Lvtao and Le, Kaixin and Fu, Weitao and Qin, Yiyang and Hou, Tingjun and Li, Dan and Sheng, Rong},
title = {Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {21},
pages = {19395--19416},
doi = {10.1021/acs.jmedchem.4c01752}
}
EUVIMED